КОМОРБИД КАСАЛЛИКЛАРИ БОР БЕМОРЛАРДА COVID-19НИ ДАВОЛАШ ХУСУСИЯТЛАРИ: ЎПКА ВА БЎЙРАКЛАРГА ТАЪСИРИ (АДАБИЁТЛАР ШАРХИ)
##article.subject##:
COVID-19, коморбидликлар, ўткир буйрак етишмовчилиги, АРДС##article.abstract##
COVID-19 пандемияси глобал соғлиқни сақлаш тизимига, айниқса олдиндан мавжуд касалликлари бор беморларга катта таъсир кўрсатди. Ушбу шарҳ COVID-19 да коморбидликлар ва касалликнинг ривожланиши ўртасидаги ўзаро боғлиқликни ўрганади, буйрак ва ўпка шикастланишига эътибор қаратади. Ўткир буйрак етишмовчилиги (ЎБЕ) ва ўткир нафас етишмовчилиги синдроми (ОРДС) айниқса сурункали буйрак касаллиги (СБК) бўлган беморларда жиддий асоратлардир. Шарҳда замонавий даволаш усуллари, жумладан буйракни ўрнини босувчи терапия (БЎТ) ва узлуксиз буйракни ўрнини босувчи терапия (УБЎТ) кабилар кўрсатилиб, оғир ҳолатларда натижаларни яхшилаганлиги таъкидланади. Даволаш стратегияларини янада такомиллаштириш ва беморларнинг соғлиқ натижаларини яхшилаш учун қўшимча тадқиқотлар талаб қилинади.
Библиографические ссылки
Index.minfin. Official data of the Ministry of Finance of the Republic of Uzbekistan, 2023. Available at: https://index.minfin.com.ua/reference/coronavirus/geography/uzbekistan/
Oyelade T., Alqahtani J., Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: An early systematic review and meta-analysis. Trop Med Infect Dis. 2020;5(2):80. doi:10.3390/tropicalmed5020080.
Guan W-J, Ni Z-Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032.
Hu L., Chen S., Fu Y., et al. Risk factors associated with clinical outcomes in 323 COVID-19 patients in Wuhan, China. Journal of Clinical Virology. 2020;127:104371. doi:10.1016/j.jcv.2020.104371.
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343-346. doi:10.15585/mmwr.mm6912e2.
Cummings M.J., Baldwin M.R., et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. 2020;395(10239):1763–1770. doi:10.1016/S0140-6736(20)31189-2.
Braun F., Lütgehetmann M., Pfefferle S., et al. SARS-CoV-2 renal tropism associates with acute kidney injury. The Lancet. 2020;396(10251):597-598. doi:10.1016/S0140-6736(20)31759-1.
Ye G., Pan Z., Pan Y., et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. Journal of Infectious Diseases. 2020;80(5). doi:10.1016/j.jinf.2020.03.001.
Van Elslande J., Vermeersch P., Vandervoort K., et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clinical Infectious Diseases. 2020; ciaa1330. doi:10.1093/cid/ciaa1330.
Nicholson E., Avadhanula V., Fragoso S., et al. SARS-CoV-2 re-infection versus prolonged shedding: A case series. Preprint. Available at: https://d197for5662m48.cloudfront.net/documents/publicationstatus/63133/preprint_pdf/4208b09a79ce5737322389d0124f4c55.pdf.
To K.K., Hung I.F., Ip J.D., et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clinical Infectious Diseases. 2021;73(9). doi:10.1093/cid/ciaa1275.
Remuzzi A., Remuzzi G. COVID-19 and Italy: what next? The Lancet. 2020;395(10231):1225–1228. doi:10.1016/S0140-6736(20)30627-9.
Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.
Pei G., Zhang Z., Peng J., et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. Journal of the American Society of Nephrology. 2020;31(6):1157–1165. doi:10.1681/ASN.2020030276.
Wang X., Fang X., Cai Z., et al. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: A systemic review and meta-analysis. Research. 2020;2020:2402961. doi:10.34133/2020/2402961.
Taverna G., Di Francesco S., Borroni E., et al. The kidney, COVID-19, and the chemokine network: an intriguing trio. International Urology and Nephrology. 2021;53:97–104. doi:10.1007/s11255-020-02579-8.
Nasiri M.J., Haddadi S., Tahvildari A., et al. COVID-19 clinical characteristics and sex-specific risk of mortality: systematic review and meta-analysis. Frontiers in Medicine. 2020;7:459. doi:10.3389/fmed.2020.00459.
Guan W.J., Liang W.H., Zhao Y., et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: A nationwide analysis. European Respiratory Journal. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020.
Rubin S., Orieux A., Prevel R., et al. Characterisation of acute kidney injury in critically ill patients with severe coronavirus disease-2019 (COVID-19). medRxiv. 2020; doi:10.1101/2020.05.06.20069872.
Sabaghian T., Kharazmi A.B., Ansari A., et al. COVID-19 and acute kidney injury: A systematic review and meta-analysis. Frontiers in Medicine. 2022;9:705908. doi:10.3389/fmed.2022.705908.
Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney International. 2020;98:209-218. doi:10.1016/j.kint.2020.05.006.
Perico L., Benigni A., Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? Nephron. 2020;144(5):213-221. doi:10.1159/000507305.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.17023.
Budhathoki P., Shrestha D.B., Rawal E., Khadka S. Corticosteroids in COVID-19: Is it rational? A systematic review and meta-analysis. SN Comprehensive Clinical Medicine. 2020;1-21. doi:10.1007/s42399-020-00515-6.
Naicker S., Yang C.W., Hwang S.J., et al. The novel coronavirus 2019 epidemic and kidneys. Kidney International. 2020;97(5):829–838. doi:10.1016/j.kint.2020.03.005.
Naicker S., Forni L.G., Mehta R.L., et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nature Reviews Nephrology. 2020;16(12):747-764. doi:10.1038/s41581-020-00356-5.
Sathyakamala R., Peace A.R., Shanmugam P., et al. A comparative study on bacterial co-infections and prevalence of multidrug resistant organisms among patients in COVID and non-COVID Intensive Care Units. Journal of Preventive Medicine and Hygiene. 2022;63(1). doi:10.15167/2421-4248/jpmh2022.63.1.2175.
Mutua J.M., Mwaniki N.J., Musyoki A.M. Multidrug resistant bacterial infections in severely ill COVID-19 patients admitted in a national referral and teaching hospital, Kenya. BMC Infectious Diseases. 2022;22:877. doi:10.1186/s12879-022-07885-3.
Fowler R.A., Lapinsky S.E., Hallett D., et al. Critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):367-373. doi:10.1001/jama.290.3.367.
Liakopoulos V., Roumeliotis S., Papachristou S., et al. COVID-19 and acute kidney injury: A pathophysiological overview. Kidney International. 2022;98:1296-1307. doi:10.1016/j.kint.2020.07.019.
Zhang H., Penninger J.M., Li Y., et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Medicine. 2020;46(4):586–590. doi:10.1007/s00134-020-05985-9.
Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
Zhang Z., Zhang L., Zha D., et al. COVID-19 and the kidney: A systematic review. The Lancet. 2020; doi:10.1016/S0140-6736(20)30566-3.
Chen Y.T., Shao S.C., Hsu C.K., et al. Incidence of acute kidney injury in COVID-19 infection: A systematic review and meta-analysis. Critical Care. 2020;24:346. doi:10.1186/s13054-020-03009-y.
WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim Guidance. 2020. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19
Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19 in New York City. Kidney International Reports. 2020; doi:10.1016/j.kint.2020.05.006.
Sterne J.A.C., Murthy S., Diaz J.V., et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.17023.
Budhathoki P., Shrestha D.B., Rawal E., et al. Risk of death associated with corticosteroid use in COVID-19 patients: A meta-analysis. Journal of Clinical Medicine. 2020;9(5):1733. doi:10.3390/jcm9051733.
Ghani R.A., Zainudin S., Kong N.T., et al. Serum IL-6 and IL-1ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology Dialysis Transplantation. 2006;11:386-393. doi:10.1111/j.1440-1797.2006.00600.x.
